Alis Biosciences is a new vehicle in healthcare investing.

We work collaboratively with listed company shareholders, management teams and boards to return the ‘trapped’ capital and resuscitate viable science and intellectual property (IP) in public, development stage life sciences and biotech companies with a negative Enterprise Value status.

In early 2025, there are nearly 300 companies worldwide with trapped capital estimated to be worth over USD$30 billion.

Alis Biosciences aims to address inefficiencies in the market by offering flexible structures and solutions to shareholders, creating a novel and much-needed market safety net.